Abstract
It is well known that many tumours are potentially immunogenic, as corroborated by the presence of tumour-specific immune responses in vivo. Nonetheless, spontaneous clearance of established tumours by endogenous immune mechanisms is rare. Therefore, the focus of most cancer immunotherapies is to supplement essential immunogenic elements to boost tumour-specific immunity. Why then has tumour immunotherapy resulted in a generally poor clinical efficiency? The reason might lie in the increasingly documented fact that tumours develop diverse strategies that escape tumour-specific immunity.
Publication types
-
Research Support, U.S. Gov't, Non-P.H.S.
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
Antigen-Presenting Cells / immunology
-
Antigens, CD
-
Antigens, Neoplasm
-
B7-1 Antigen / immunology
-
B7-H1 Antigen
-
Combined Modality Therapy
-
Dendritic Cells / immunology
-
Humans
-
Immune Tolerance*
-
Immunotherapy
-
Membrane Glycoproteins / immunology
-
Neoplasms / immunology*
-
Neoplasms / therapy
-
Peptides / immunology
-
T-Lymphocyte Subsets / immunology
-
Tumor Escape*
Substances
-
Antigens, CD
-
Antigens, Neoplasm
-
B7-1 Antigen
-
B7-H1 Antigen
-
CD274 protein, human
-
Membrane Glycoproteins
-
Peptides